Related Experiment Video
Updated: Jul 19, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[PET and PET/CT in relapsing prostate carcinoma]
S N Reske1, N M Blumstein, G Glatting
1Klinik für Nuklearmedizin, Universitätsklinikum, Robert-Koch-Strasse 8, 89081, Ulm, Germany. sven.reske@uniklinik-ulm.de
Der Urologe. Ausg. A
|September 29, 2006
Summary
Recurrent prostate cancer detection is crucial for treatment. Modern fusion imaging, like PET/CT, accurately localizes recurring tumors, guiding therapy decisions.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Context:
- Prostate cancer recurrence affects 15-23% of patients treated with curative intent.
- Accurate localization of recurrent prostate cancer is essential for choosing between local or systemic therapies.
- Salvage therapy is required for 16-35% of patients within 5 years of initial treatment.
Purpose:
- To evaluate the role of modern fusion imaging in localizing recurrent prostate cancer.
- To assess the diagnostic performance of PET/CT with 11C/18F-choline or 11C-acetate in detecting recurrent disease.
- To highlight the potential of fusion imaging for early detection and precise anatomical localization of prostate cancer relapse.
Summary:
- Fusion imaging techniques, particularly PET/CT with 11C/18F-choline or 11C-acetate, significantly enhance the diagnostic capabilities for assessing relapsing prostate cancer.
- These advanced imaging modalities can detect and precisely localize recurrent tumors in 60-70% of patients experiencing biochemical relapse.
- Detection sensitivity is influenced by serum prostate-specific antigen (PSA) levels, with lower PSA concentrations (below 1 ng/ml) showing a mean detection sensitivity of 50-66%.
Impact:
- Fusion imaging, especially when combined with MRI, offers high potential for the early and accurate localization of recurrent prostate carcinoma.
- Improved localization facilitates the selection of optimal, personalized therapeutic strategies, potentially improving patient outcomes.
- This technology advances the management of prostate cancer by providing precise anatomical information for treatment planning.
Related Concept Videos
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET